Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor |
| November 06, 2019 | November 2019 Bond Updates |
|
CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 /PRNewswire/ -- Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-licensing by Artios of a... |
| View more at: https://www.prnewswire.com:443/news-releases/artios-pharma-md-anderson-and-shangpharma-announce-in-licensing-agreement-for-dna-damage-response-inhibitor-300952071.html |
| Related News |
|